극한의 조합 바이애슬론

임명철 한국스포츠과학원 2025 스포츠과학 Vol.173 No.0

Role of high risk-human papilloma virus test in the follow-up of patients who underwent conization of the cervix for cervical intraepithelial neoplasia

임명철 대한부인종양학회 2009 Journal of Gynecologic Oncology Vol.20 No.3

Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010

임명철,문은경,신애선,정규원,원영주,서상수,강석범,김재원,김주영,박상윤 대한부인종양학회 2013 Journal of Gynecologic Oncology Vol.24 No.4

Objective: To investigate the recent incidence of and trends in cervical, endometrial, and ovarian cancer in Korean females. Methods: Data from the Korea Central Cancer Registry between 1999 and 2010 were analyzed. Age-standardized rates (ASRs) and annual percent changes (APCs) were calculated. Results: The absolute incidence rates of the three major gynecologic cancers increased: 6,394 in 1999 to 7,454 in 2010. The ASR for gynecologic cancer was 23.7 per 100,000 in 1999 and decreased to 21.0 in 2010 (APC, -1.1%; 95% confidence interval [CI], -1.53 to -0.70) due to a definitive decrease in the incidence of cervical cancer (APC, -4.3%). Endometrial cancer has been definitively increasing (APC, 6.9% during 1999-2010), especially in females <30 years old (APC, 11.2%) and in females ≥80 years old (APC, 9.5%). The incidence of ovarian cancer is increasing gradually (APC, 1.5%). Conclusion: ASRs and APC for gynecologic cancers overall are decreasing due to the decrease in the incidence of cervical cancer. However, the incidence of endometrial and ovarian cancer has been increasing.

마음챙김 기반 인지치료(MBCT)가 부정적인 신체상을 가진 대학생의 신체상 만족도, 불안 및 자아존중감에 미치는 효과

임명철,손정락 한국건강심리학회 2012 한국심리학회지 건강 Vol.17 No.4

The purpose of this study is to explore the effects of Mindfulness-Based Cognitive Therapy (MBCT) on Body Image Satisfaction, Anxiety, and Self-Esteem in University Students with negative body image. Five hundred ten university students who lived in Chonbuk province completed the Body Esteem Test, Body Cathexis Scale, Beck Anxiety Inventory Scale and Self Esteem Scale. Eighteen patients who selected by those scales were randomly assigned to 9 in the MBCT group, and 9 in the waiting-list control group. All participants completed Body Esteem Test, Body Cathexis Scale, Beck Anxiety Inventory Scale and Self Esteem Scale at pretreatment, end of treatment, and at 4 weeks follow-up periods. MBCT program was administered for 8 sessions. The results of this study were as follows: Body Image Satisfaction(Body Esteem, Body Cathexis), Self-Esteem of therapy group were increased more than those of the waiting-list control group, and Anxiety was decreased in the therapy group. Finally, implications and limitations of this study and suggestions for future study are also discussed. 본 연구는 마음챙김 기반 인지치료(MBCT)프로그램이 대학생의 신체상 만족도, 불안 및 자아 존중감에 미치는 효과를 알아보았다. 사전 조사에서 신체 존중감 검사, 신체 만족 척도, Beck 불안 항목표, 자아 존중감 척도를 실시하여, 이를 토대로 24명을 선발하여 마음챙김 기반 인지치료 집단에 12명, 대기통제집단에 12명으로 무선할당 하였다. 치료집단에 대해 총 8회기에 걸쳐 마음챙김 기반 인지치료 프로그램을 실시하였다. 신체상 만족도(신체 존중감 검사, 신체 만족 척도), 불안 및 자아 존중감 수준은 사전, 사후 1개월 추적 기간 동안 검사를 통해 18명의 참가자(MBCT 프로그램 9명, 대기통제집단 9명)에 대한 평가가 이루어졌다. 본 연구의 결과, 마음챙김 기반 인지치료 프로그램에 참여한 집단이 대기통제집단보다 신체상 만족도와 자아 존중감이 증가되었고 불안이 감소되었으며 그 수준이 추적검사까지 유지되었다. 마지막으로 본 연구의 의의, 제한점 및 후속 연구를 위한 시사점이 논의되었다.

Allogeneic Blood Transfusion Given Before Radiotherapy Is Associated with the Poor Clinical Outcome in Patients with Cervical Cancer

임명철,김태현,박소희,공선영,윤정현,강석범,서상수,박상윤,김주영 연세대학교의과대학 2008 Yonsei medical journal Vol.49 No.6

Purpose: To analyze the effect of allogeneic blood transfusion on clinical outcome in 119 patients with stage IIB cervical cancer who were treated with radiotherapy±chemotherapy. Patients and Methods: Medical records were examined for hemoglobin levels before and during radiotherapy, history of allogeneic blood transfusions and the time point when transfusions were given. These factors were retrospectively analyzed along with other clinical risk factors for influences on the patients’ clinical outcomes. Results: Thirty-two patients (26.9%) received packed red blood cell transfusion (mean, 3.4 units; range, 1-12 units) before or during radiotherapy. Median follow-up period was 39.3 months (range, 7.6-58.4 months). Patients with history of transfusion showed poorer metastasis- free survival and a trend toward poorer overall survival than non-transfused patients. When patients who received transfusions were sub-divided by the time of transfusion, those who received transfusions before radiotherapy had significantly poorer clinical outcome than those who received transfusions during radiotherapy. In a multivariable analysis, patients with pretreatment transfusion showed a higher risk of distant metastasis (HR=3.75, 95% CI: 1.28-12.15, p=0.017) and decreased overall survival rates (HR=4.62, 95% CI: 1.15-18.54, p=0.031) compared with those of other patients. Conclusion: Our results suggest that allogeneic blood transfusions given before radiotherapy may be associated with higher incidence of distant metastases and decreased survival in patients with stage IIB cervical cancer.

CHIPOR, HORSE, and beyond: unraveling the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

임명철 대한부인종양학회 2025 Journal of Gynecologic Oncology Vol.36 No.1

The advantage of hyperthermic intraperitoneal chemotherapy (HIPEC) is that it maintainsdirect exposure of anticancer drugs to the tumor while avoiding the use of intraperitonealports, which makes less complication from intraperitoneal chemotherapy while maintainingthe sur vival benefit [1]. An additional advantage is that the chemotherapeutic agent can beexposed to the entire visceral and parietal peritoneum before adhesions occur after surger y. In addition, hyperthermia can be added, which is a great advantage in that it makes the tumormore BRCAness-like and increases its response to anticancer drugs [2]. In 2018, the OVHIPEC-01 trial, the first phase III randomized trial in ovarian cancerperformed by van Driel et al. [3], reported that HIPEC increases progression-free sur vival(PFS) and overall sur vival (OS) when inter val cytoreductive surger y is performed afterneoadjuvant chemotherapy in stage III ovarian cancer. In 2022, Lim et al. [4] reported thatthere was no sur vival benefit of HIPEC during upfront surger y in the KOV-HIPEC-01 trial, butas in the OVHIPEC-01 trial, HIPEC increased PFS and OS when inter val cytoreductive surger ywas performed after neoadjuvant chemotherapy. A meta-analysis later demonstrated that HIPEC is beneficial for sur vival in cases of recentexposure to chemotherapy within 6 months [5]. In the recent chemotherapy exposure group(<6 months), HIPEC was associated with improvement of both PFS (hazard ratio [HR]=0.585;95% confidence inter val [CI]=0.422–0.811) and (≥6 months) OS (HR=0.519; 95% CI=0.346–0.777), while in the non-recent chemotherapy exposure group, HIPEC failed to significantlyaffect PFS (HR=1.037; 95% CI=0.684–1.571) or OS (HR=0.932; 95% CI=0.607–1.430). The CHIPOR and HORSE studies further contributed to the understanding of HIPEC’s rolein ovarian cancer [6,7]. The HORSE trial evaluated HIPEC in the first-recurred platinum-sensitive recurrent ovarian cancer during secondar y cytoreductive surger y but found nosignificant benefit in either PFS (median PFS: 16.9 vs. 15.7 months; HR=0.97, p=0.863) orOS (median OS: 53.8 vs. 52.6 months; HR=0.96, p=0.870) [6]. However, the CHIPOR trialdemonstrated a significant sur vival benefit by administering 6 cycles of platinum-basedchemotherapy to patients with platinum-sensitive recurrent ovarian cancer, followed byconsolidation HIPEC after cytoreductive surger y [7]. It showed a significant improvementin OS with HIPEC (median OS: 54.3 vs. 45.8 months; HR=0.73, p=0.024), supporting itsapplication in selected cases. These 2 findings further support the hypothesis that HIPEC might offer clinical benefits incases where recent chemotherapy exposure has occurred, and the tumor is resectable. Theirfindings may be explained by previously proposed hypotheses that hyperthermia can renderchemo-resistant cancer cells more susceptible to chemotherapy. The rationale for this effectlies in heat-induced inhibition of HSP90, which disrupts DNA damage repair pathways andpromotes the degradation of BRCA1/2 proteins, thereby sensitizing cells to the DNA damagecaused by platinum-based chemotherapy [8,9]. In this consistent context, HIPEC is expected to provide a sur vival benefit in platinum-resistant recurrent ovarian cancer. However, since the role of cytoreductive surger y is unclearin this setting, we can look for ward to the results of the KOV-HIPEC-02R (RECOVER) trial,which is currently registered in more than 80% and is expected to produce results within 2–3years (NCT05316181). In primar y ovarian cancer, the OVHIPEC-02 trial has been registeredfor more than 3-quarters of targeted number of the stage III patients after upfront surger y(NCT03772028). The role of HIPEC during inter val cytoreductive surger y after neoadjuvantchemotherapy in stage III and IV patients with maintenance therapy with poly(ADP-ribose) polymerase inhibitors or bevacizumab is evaluated in the ongoing KOV-04, FOCUS(enrollment >50%, target number: 520) (NCT05827523)....

난소암의 항암요법

임명철,박상윤 대한의사협회 2016 대한의사협회지 Vol.59 No.3

The standard treatment for epithelial ovarian cancer is maximal cytoreductive surgery and adjuvant chemotherapy. Neoadjuvant chemotherapy can be considered as an alternative treatment strategy when unacceptable primary surgery, in terms of gross residual tumor remaining at the end of cytoreduction, is expected or in cases where poor general condition renders extensive cytoreductive surgery unsuitable. Intraperitoneal chemotherapy is ideal for epithelial ovarian cancer because its spread is mainly limited to the peritoneal cavity. Several randomized controlled trials have reported a survival gain with intraperitoneal chemotherapy. However, disadvantages such as port-related complications, abdominal pain, and neurotoxicity hinder its wide use. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has been suggested as an alternative treatment strategy for intraperitoneal chemotherapy. Ongoing clinical trials of hyperthermic intraperitoneal chemotherapy will quantify clinical outcomes in the future, such as the survival benefit in epithelial ovarian cancer.

Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

임명철,이마리아,심승혁,남은지,이정윤,김현정,이유영,이광범,박정열,김윤환,기경도,송영정,정현훈,김성훈,이정원,김재원,배덕수,이종민 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.3

Clinical practice guidelines for gynecologic cancers have been developed by academic society from several countries. Each guideline reflected their own insurance system and unique medical environment, based on the published evidence. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to develop the third edition of the guidelines in an advanced format based on evidence-based medicine, embracing up-to-date clinical trials and qualified Korean data. These guidelines cover strategies for diagnosis and treatment of primary and recurrent cervical cancer. The committee members and many gynecologic oncologists derived key questions through discussions, and a number of relevant scientific literature were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, along with the details. The objective of these practice guidelines is to establish standard policies on issues in clinical practice related to the management in cervical cancer based on the results in published papers to date and the consensus of experts as a KSGO Consensus Statement.

Different role of secondary cytoreductive surgery by surgeon's experience and hospital facility

임명철,박상윤,배재만 대한부인종양학회 2009 Journal of Gynecologic Oncology Vol.20 No.3

유전성 부인암의 최신지견

임명철 대한산부인과학회 2024 대한산부인과학회 연수강좌 Vol.70 No.0